Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Discontinuation Study of Brivanib Alaninate in Advanced Solid Tumors
2008-000087-16Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of brivanib alaninate in Nonhematologic neoplasms and advanced nonhematological malignancy (3 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Progression-free survival (PFS). Started Mar 2008; status: completed.
02
Drugs
brivanib alaninate
03
Conditions
Nonhematologic neoplasmsadvanced nonhematological malignancy
Beyond the preview
Go deeper on 2008-000087-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000087-16.